Key result
Recombinant VSIG3 lowers cardiac mitochondrial vesicle release by ~9 percentage points in ischemia-reperfusion.
Why the study?
Myocardial ischemia-reperfusion injury remains a severe challenge characterized by mitochondrial dysfunction and CD4+ T cell infiltration, prompting investigation into the therapeutic potential of VSIG3.
Does recombinant VSIG3 administration mitigate myocardial ischemia-reperfusion injury, preserve mitochondrial homeostasis, reduce mitochondrial-derived vesicle release, and restrain CD4+ T-cell infiltration in preclinical models?
Does recombinant VSIG3 administration mitigate myocardial ischemia-reperfusion injury, preserve mitochondrial homeostasis, reduce mitochondrial-derived vesicle release, and restrain CD4+ T-cell infiltration in preclinical models?
Preclinical evidence demonstrates that recombinant VSIG3 protects against myocardial ischemia-reperfusion injury in mice by preserving mitochondrial homeostasis, reducing cytotoxic mitochondrial-derived vesicle release, and restraining myocardial CD4+ T-cell infiltration.
Answers are grounded in this paper and cite their sources.
Recombinant VSIG3 may attenuate MI/R injury in mice; hypothesis-generating for VSIG3-targeted therapy before clinical translation.
Myocardial ischemia-reperfusion (MI/R) injury remains an inevitable and severe clinical challenge during cardiac surgery, primarily characterized by mitochondrial dysfunction and robust CD4 + T cell infiltration. In this study, we investigated the therapeutic potential of the immune checkpoint molecule VSIG3 (V-set and transmembrane domain-containing protein 3) in mitigating MI/R injury. In clinical samples, ELISA-detectable VSIG3-related plasma immunoreactivity of an undefined molecular form was associated with myocardial injury and inflammation. Recombinant VSIG3 administration improved cardiac function in MI/R mice and was accompanied by lower cardiac extracellular vesicle (EV) levels, including a reduction in TOMM20⁺ mitochondrial-derived vesicle (MDV)-related signals. In vitro, VSIG3 attenuated apoptosis, enhanced antioxidant capacity, and preserved mitochondrial metabolism, accompanied by an associated increase in PI3K/Akt/mTOR phosphorylation at 3 h post-injury. Exogenous MDV supplementation partially counteracted the cytoprotective effects observed with VSIG3 treatment. In vivo, VSIG3 treatment reduced CD4 + T cell infiltration and suppressed inflammatory cytokines (TNF-α, IL-17α, IL-21) in myocardial tissue. In summary, exogenous MDVs behaved as detrimental stimuli in the present experimental settings, whereas VSIG3 treatment was accompanied by reduced MDV release, improved mitochondrial homeostasis, and suppressed T-cell activation. These findings support an association between VSIG3 treatment and MDV-related changes in MI/R injury, but do not establish MDV suppression as a necessary or sufficient mediator of VSIG3-mediated cardioprotection.
No takes yet. Share an insight, caveat, or question.
Hou et al. (2026) studied Myocardial ischemia-reperfusion injury (MI/R) and heart valve disease (n=172). Recombinant VSIG3 protein vs. Vehicle control (I/R + PBS) and matched protein/tag control (I/R + MSA-His) was evaluated on Cardiac tissue TOMM20+ mitochondrial-derived vesicle (MDV) proportion of total extracellular vesicles (p=<0.05). Recombinant VSIG3 administration lowered cardiac TOMM20+ MDV proportion and reduced cTnT to 75.02% of control levels in MI/R mice.
Synapse has enriched 10 related papers. Consider them for comparative context: